摘要
目的:探讨益气软肝方联合恩替卡韦治疗慢性肝炎肝纤维化的临床效果。方法:选择2012年9月至2015年2月在我院内科治疗的慢性肝炎肝纤维化患者98例,采用随机抽签方法分为治疗组与对照组各49例,对照组给予恩替卡韦治疗,治疗组给予益气软肝方联合恩替卡韦治疗,都治疗3个月。对治疗后两组疗效、肝功能指标及肝纤维化指标进行检测与比较。结果:治疗后治疗组的总有效率为98.0%,对照组为85.7%,治疗组总有效率明显高于对照组(P<0.05)。与治疗前相比,治疗后两组肝功能指标均有所改善(P<0.05),治疗后两组肝功能指标对比差异不明显(P>0.05)。两组治疗后的血清HA、CⅣ、PCⅢ和LN值都明显低于治疗前(P<0.05),同时与对照组相比,治疗后治疗组的血清HA、CⅣ、PCⅢ和LN值明显较低(P<0.05)。结论:益气软肝方联合恩替卡韦治疗慢性肝炎肝纤维化能提高治疗疗效,改善肝功能指标及肝纤维化指标,其作用机制可能与降低肝纤维化因子的释放有关。
Objective： To investigate the clinical effects of Yi Qi Ruan Gan soup combined with entecavir for treatment of chronic hepatitis liver fibrosis. Methods： From September 2012 to February 2015, selected 98 patients with chronic hepatitis liver fibrosis in our hospital were equally divided randomly into treatment group and control group. The patients in control group received entecavir treatment, and the patients in treatment group were given Yi Qi Ruan Gan soup combined with entecavir treatment, and all treatment cycles were three months. Then the efficacy, indexes of liver function and liver fibrosis indexes were examined and compared. Results： After treatment, the total effective rate in the treatment group and the control group were 98.0 % and 85.7 % respectively, which were significantly higher in treatment group with statistical significance compared with control group（P〈0.05）. The index of liver function after treatment were all improved with significant difference compared with before treatment（P〈0.05）. But the difference of index of liver function between two groups after treatment was no statistically significance（P〉0.05）. After treatment, the serum level of HA, CⅣ, PCⅢ and LN were significantly lower than before treatment（P〈0.05）, while the serum level of HA, CⅣ, PCⅢ and LN in the treatment group after treatment were significantly lower than that of the control group（P〈0.05）. Conclusions： Yi Qi Ruan Gan soup combined with entecavir for treating chronic hepatitis liver fibrosis could improve the therapeutic efficacy, improve the indexes of liver function index and hepatic fibrosis, and its mechanism may be associated with reducing the release of liver fibrosis cytokines.
出处
《现代生物医学进展》
CAS
2016年第17期3291-3294,共4页
Progress in Modern Biomedicine
